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Abstract
Background—Few studies have assessed associations of surgeons’ practice volume with
processes of care that lead to better outcomes.
Objective—We surveyed surgeons treating colorectal cancer to determine whether high-volume
surgeons were more likely to collaborate with other physicians in decisions about adjuvant
therapies.
Subjects and methods—Surgeons caring for patients with colorectal cancer in multiple
regions and health-care organizations were surveyed to assess their volume of colorectal cancer
resections and participation in decisions about adjuvant chemotherapy and radiation therapy. We
used logistic regression to assess physician and practice characteristics associated with surgical
volume and the relation of surgical volume and these other characteristics to collaborative
decision-making regarding adjuvant therapies.
Results—Of 635 responding surgeons, those who identified themselves as surgical oncologists
or colorectal surgeons were more likely than others to report high volume of colorectal cancer
resections (p<.001), as were those who practiced at a comprehensive cancer center (P=.06) and
attended tumor board meetings weekly (vs. quarterly or less, P=.09). Most surgeons reported a
collaborative role in decisions about chemotherapy and radiation therapy. However, in adjusted
analyses, higher-volume surgeons more often reported a collaborative role with other physicians in
decisions about chemotherapy (P<0.001) and radiation therapy (P<0.001).
Conclusions—Higher-volume surgeons are more likely to report collaborating with other
physicians in decisions about adjuvant therapies for patients following colorectal cancer surgery.
This collaborative decision-making of higher-volume surgeons may contribute to outcome
differences by surgeon volume.
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INTRODUCTION
Higher hospital and surgeon volumes have been associated with improved patient outcomes
for many operations.1, 2 For patients with colorectal cancer, a cancer diagnosed in nearly
150,000 Americans every year,5 greater surgical and hospital volume are associated with
improved outcomes.6-17 Patients of higher-volume surgeons receive permanent colostomies
less frequently and have lower mortality compared with patients of lower-volume
surgeons.7-10, 12, 16 Moreover, volume is significantly associated with use of guideline-
recommended therapies, such as adjuvant chemotherapy for node-positive colorectal
cancer,18 and hospital volume is strongly associated with use of adjuvant radiation
therapy.16 These findings raise the question as to how care delivered by higher-volume
surgeons following cancer surgery might differ from that of lower-volume surgeons.
The Leapfrog Group, a consortium of healthcare purchasers, has used volume explicitly as a
proxy for quality by mandating selective referrals for certain high-risk operations.3 For some
complex cancer operations, such as esophagectomies and pancreatectomies that require
specialized expertise and resources, selective referral may be a reasonable strategy to
improve surgical outcomes. However, for common operations such as resection of colorectal
cancer performed in many hospitals, often emergently or urgently, selective referral may be
less feasible to improve the quality of surgical care because of limited capacity at high-
volume hospitals and patient preferences for care in local hospitals.4 A more effective
strategy may be to identify differences in practice patterns for high- and low-volume
surgeons in processes of care that may be linked to superior outcomes. Hospitals and
surgeons could then be assisted in adopting such “best practices”. However, the practice
patterns or processes of care by high-volume surgeons that lead to these outcome differences
for patients are not well defined.
This study assessed a previously unexplored, potentially mutable factor that may contribute
to these volume-outcome relationships: coordination of care between surgeons and other
physicians who care for patients with colorectal cancer. We surveyed surgeons caring for
patients with colorectal cancer with two goals. First, we assessed whether surgeons’
demographic and practice characteristics were associated with their volume of colorectal
cancer resections. Second, we examined whether high-volume surgeons were more likely
than lower-volume surgeons to collaborate with other physicians when making decisions
about adjuvant chemotherapy and radiation therapy.
METHODS
Study cohort
Surveys of surgeons were conducted by the Cancer Care Outcomes Research and
Surveillance (CanCORS) Consortium, a large multi-regional study examining processes and
outcomes of care for patients with lung or colorectal cancer.19, 20 The CanCORS study
examined care delivered to a population-based cohort of more than 10,000 patients newly
diagnosed with lung or colorectal cancer during 2003-2005 who were living in Northern
California, Los Angeles County, North Carolina, Iowa, or Alabama, or who received care in
one of 5 large health plans or one of 10 Veteran's Administration hospitals. The human
subjects committees at all participating institutions approved the study protocol.
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As previously described, 21 we surveyed physicians named by patients as providing
important roles in their care. Of the 6871 physicians whose contact information was verified,
4188 (61.0%) responded, including 62.5% of surgeons. For this analysis, we restricted the
sample to the 651 physicians who identified themselves as surgeons who cared for at least
one patient with colorectal cancer in the past year. We excluded 16 surgeons from the Iowa
site, because no colorectal cancer patients were enrolled at this site, for a final cohort of 635
surgeons. Further information on the survey is provided in the Appendix. Data collection
was closed and the dataset (version 1.6.1) finalized in March 2007.
Survey Instrument
The survey collected surgeons’ characteristics including race/ethnicity, gender, board
certification, and year of graduation from medical school, U.S./Canadian training, and self-
reported specialty. We also collected information on number of colorectal cancer resections
each surgeon performed per month, participation in teaching, practice setting, percentage of
patients in managed care, whether the physician practiced at a National Cancer Institute
comprehensive cancer center, whether their practice was part of the Community Clinical
Oncology Program, and reported attendance at tumor board meetings. Surgeons were also
asked how they typically made decisions about possible use of chemotherapy and about
possible use of radiation chemotherapy for patients. Response options for each question
were: (1) I provide this care myself without much input from another clinician; (2) I co-
manage or decide jointly on this care with another clinician; (3) I refer patients to another
clinician for this care; and (4) I am not involved in this care. Because we were specifically
interested in collaboration and relatively few physicians reported deciding themselves or not
being involved in care, we dichotomized the responses as co-managing/deciding jointly vs.
all other responses.
Survey Administration
We mailed each physician a self-administered survey with a check or non-cash incentive
that varied by site, ranging in value from $20 to $50. Non-respondents were mailed another
survey after 3 weeks. After another 3 weeks, we telephoned their offices to encourage
completion of the survey, and additional questionnaires were sent on request. At one site,
initial contact occurred via electronic mail; at other sites, electronic mail was used for
follow-up of non-responders. All physicians were given the option to complete the survey
via a secure Internet site, and 13% of respondents chose this option.
Statistical analysis
We calculated the volume of colorectal cancer resections performed during the past month
and categorized volume in quartiles. We used chi-square tests to assess physician and
practice characteristics (categorized as in Table 1) associated with volume in the top
quartile. For all analyses, we combined colorectal surgeons and surgical oncologists because
their responses were similar. We also used chi-square tests to assess the association of
surgical volume and other physician and practice characteristics with collaborative decision-
making regarding chemotherapy and radiation therapy (defined as reporting that they co-
managed or decided jointly about these therapies versus deciding themselves, referring to
another provider, or not being involved in these decisions).
We used multivariable logistic regression models to identify surgeon characteristics
associated with high surgical volume (top quartile). Independent variables included
surgeons’ demographic and practice characteristics described above that were associated
with high surgical volume (p≤0.20) in bivariate analyses. Similarly, we used multivariable
logistic regression models to examine the association between surgical volume and
collaborative care for (1) chemotherapy decisions and (2) radiation therapy decisions,
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controlling for physician and practice characteristics with P value ≤.20 in unadjusted
analyses examining the relationship between each characteristic and collaboration about
chemotherapy or radiation therapy, respectively.
Item non-response was less than 3% for most variables. Values were multiply imputed.22,23
All tests of statistical significance were two-sided. We conducted analyses using SAS
statistical software, version 9.1.3 (SAS Institute, Inc., Cary, North Carolina).
RESULTS
Of the 635 surgeons in the study cohort, most (84%) were general surgeons (Table 1). The
median time since medical school graduation was 24 years (first and third quartiles, 15 to
31). Most responding surgeons were male (89.5%), non-Hispanic white (74.1%), board-
certified (94.6%), and US or Canadian medical school graduates (88.3%). Nearly half
(48.0%) of the surgeons worked in hospital-based practices. The mean (SD) number of
colorectal cancer resections performed each month was 3.1 (2.5).
When asked how they typically made decisions about chemotherapy, 1.4% stated that they
provide this care themselves without much input from another clinician; 61.0% stated that
they co-managed or decided jointly on this care with another clinician; 36.9% stated that
they referred patients to another clinician for this care; 0.8% stated that they were not
involved in this care.
For decisions on radiotherapy, 3.5 % stated that they provide this care themselves without
much input from another clinician; 65.3% stated that they co-managed or decided jointly on
this care with another clinician; 30.4% stated that they referred patients to another clinician
for this care; 0.8% stated that they were not involved in this care.
Factors associated with high surgical volume
When we examined characteristics of surgeons in the highest volume quartile (≥5 colorectal
cancer resections per month) in unadjusted analyses, colorectal surgeons or surgical
oncologists were more likely than general surgeons to be high-volume surgeons(P<.001), as
were surgeons who were board certified (P=.045), participatep in teaching (P=.01), worked
in hospitals or group practice (vs. solo practice) (P=.02), practiced at a National Cancer
Institute-designated Cancer Center (P=.003), and attended tumor board meetings regularly
(P<.001). Year of graduation, sex, race/ethnicity, board certification, graduation from a U.S.
or Canadian medical school, proportion of patients in managed care, practice part of a
CCOP, and study site were not significantly associated with volume.
In multivariable analyses, colorectal surgeons and surgical oncologists were more likely
than general surgeons to perform a high volume of colorectal cancer resections (Table 2).
Physicians practicing at a NCI-designated cancer center and those attending tumor board
meetings weekly (vs. quarterly or less frequently) were also more likely to perform a high
volume of colorectal surgeries, although these associations did not reach statistical
significance. The surgeons in North Carolina were less likely to be high-volume surgeons
than the surgeons in Los Angeles County.
Factors associated with collaborative decision-making
Compared with lower-volume surgeons, higher-volume surgeons more often reported
collaborating with other physicians in decisions about chemotherapy (P<0.001) and
radiation therapy (P<0.001) (Table 3).
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These relationships persisted in multivariate analyses for both chemotherapy (Table 4) and
radiation therapy (Table 5). Several other characteristics were also significantly associated
with reporting collaborative decision-making for both adjuvant therapies. Colorectal
surgeons and surgical oncologists were more likely than general surgeons to report
collaborative care in decisions about both chemotherapy and radiation therapy. Surgeons
who participated in tumor boards weekly or monthly were more likely to report that they co-
managed or decided jointly about both adjuvant therapies than those attending tumor boards
quarterly or less frequently. Physicians with a higher proportion of patients enrolled in
managed care were less likely to report collaborative decisions about both adjuvant
treatments, controlling for other practice characteristics (Tables 4 and 5).
In addition, U.S./Canadian medical school graduates (versus other physicians) and surgeons
whose practice is part of a Community Clinical Oncology Program, and surgeons in the
study site consisting of 5 health maintenance organizations reported the highest rates of
collaboration in decisions about chemotherapy (Table 4).
DISCUSSION
In a large multi-regional cohort of surgeons treating patients with colorectal cancer,
colorectal surgeons and surgical oncologists were more likely than general surgeons to
perform a high volume of colorectal cancer resections, as were surgeons who practiced at
NCI-designated cancer centers and those who attended weekly tumor board meetings
(although these latter two findings were of borderline statistical significance). We found
important differences between higher- and lower-volume surgeons in their tendency to
collaborate when making decisions about possible use of adjuvant therapy. Controlling for
physician and practice characteristics, higher-volume surgeons were more likely than lower-
volume surgeons to report collaborative patterns of care regarding decision making about
adjuvant chemotherapy and radiation therapy. Although we cannot demonstrate causal
relationships, such collaboration may contribute to the greater likelihood that patients of
high-volume surgeons receive appropriate adjuvant therapies.18 This collaboration may thus
be a partial mediator of greater adherence to evidence-based guidelines for adjuvant
therapies observed among patients of high-volume providers of colorectal cancer care.
Prior studies suggest greater collaboration of care may help to improve the quality of
colorectal cancer care delivered. Referral to a medical oncologist has been identified as one
of the key factors associated with receipt of chemotherapy,15, 17 which has been reported as
limited in many individuals with stage III colon cancer, particularly older patients.9, 14, 15
Because surgeons play a major role in referring patients to medical oncologists and radiation
oncologists, patients of surgeons who collaborate more with these specialists may be more
likely to be referred to medical oncologists and radiation oncologists and receive indicated
adjuvant therapies. One study found that many physicians held views opposite to guidelines
recommending adjuvant chemotherapy and radiation therapy for stage II and III rectal
cancer.23 Greater collaboration of surgeons with medical oncologists and radiation
oncologists may increase sharing of knowledge about evidence-based guidelines and help to
prevent underuse of recommended adjuvant therapies.
Although high procedure volume may be associated with better operative technique, it may
also serve as a proxy for the performance of other recommended processes of care.7 One
study found that worse colon cancer outcomes in low-volume hospitals were not explained
by cancer recurrence11 and suggested that it may be related to worse care of comorbid
conditions (which may also rely heavily on collaboration), leading authors to advocate for a
greater focus on multidisciplinary aspects of hospital care for improving patient outcomes.12
On the other hand, because rectal cancer surgery may be more technically challenging,
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surgical volume may still be important for optimizing rectal cancer outcomes related to
intraoperative techniques, particularly the likelihood of permanent colostomy8, 16 and the
use of total mesorectal excision to prevent local recurrences.
In this study, colorectal surgeons and surgical oncologists tended to perform a higher-
volume of colorectal resections than general surgeons. Even after controlling for surgical
volume, they were more likely to report collaborating with other physicians regarding
decisions about adjuvant therapy. Because their practice is more focused on colorectal
cancer patients, they may have stronger relationships with medical and radiation oncologists,
making collaborative decisions more feasible. Surgeons who perform many colorectal
cancer resections are more focused on colorectal cancer and may thus be more able to form
collaborative relationships with other providers who care for these patients.
Not all colorectal cancer patients will go to a high colorectal cancer volume center and
neither will they all go to a colorectal or cancer specialty surgeon. For these patients,
systems of care that facilitate collaborative interactions may be needed. For example, tumor
boards could provide this structure for the co-management of colorectal cancer patients.
Systems to facilitate regular attendance at tumor board meetings may increase opportunities
for surgeons to have collaborative interactions with medical and radiation oncologists,
which may increase the likelihood of recommending appropriate adjuvant therapies. In one
study, presentation of a patient's case at a tumor board predicted receipt of recommended
therapy for rectal cancer.14
Multidisciplinary collaboration may be challenging for surgeons in rural settings or solo
practices, as there may be few medical oncologists and radiation oncologists with whom to
collaborate. Telemedicine services may be one option to provide for just-in-time
consultations with medical oncologists to facilitate co-management options for surgeons
who do not have opportunities for regular interactions with other cancer specialists.
Strengths of our study included a large cohort of surgeons who performed colorectal cancer
resection practicing in diverse geographic areas and health-care organizations and our
response rate among surgeons of 62.5%.24 However, the study had several limitations. First,
surgeons’ self-reported their approach to decision-making about adjuvant therapies, and
their responses may be subject to recall bias or social desirability bias. Second, surgeons
may have incorrectly self-reported their surgical volume, although this would likely result in
random error rather than a systematic bias. Third, our cross-sectional data allow us to
observe associations but cannot determine causal relationships between surgical volume and
collaborative decision-making about adjuvant therapies. It is possible that surgeons who
collaborate frequently have higher-volume practices than others because their collaborators
refer patients to them. Fourth, although we demonstrate more collaborative care among
high-volume surgeons, we are not able to demonstrate that this is the mechanism for higher
rates of adjuvant therapy (or improved outcomes) among patients of high-volume surgeons.
Future research will be important to examining these relationships further. Finally, because
our sample was not a national sample and the survey is subject to non-response bias, we
cannot be certain that the surgeons in our sample were representative of surgeons caring for
cancer patients nationally or in the regions studied.
In conclusion, the active collaboration by surgeons in decisions about adjuvant therapies
may be a potential mechanism for the better outcomes observed in other studies for patients
with colorectal cancer treated by high-volume surgeons.7-10, 12, 16 Additional research is
needed to confirm whether better collaboration between surgeons and other providers about
adjuvant chemotherapy and radiation for patients with colorectal cancer leads to better
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outcomes. Such research will help to disentangle the relative contributions of hospital and
surgical volume, structure, and processes of care to explain these outcome differences.
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Table 1
Characteristics of participating surgeons and unadjusted associations with high surgical volume for colorectal
cancer
Physician Characteristics Proportion of surgeons
(N=635)




    General surgeon 83.9 15.3 <0.001
    Colorectal surgeon/surgical oncologist 16.1 54.5
Year of medical school graduation
    1952-1973 23.0 15.3 0.15
    1974-1981 26.3 20.7
    1982-1990 26.1 24.9
    1991-2001 24.6 24.7
Gender
    Male 89.5 21.5 0.85
    Female 10.5 22.3
Race
    Non-Hispanic white 74.1 21.8 0.91
    Asian 15.9 20.0
    Other race 9.9 22.5
Board certified
    Yes 94.6 20.8 0.05
    No 5.4 35.3
US or Canadian medical graduate
    Yes 88.3 21.8 0.66
    No 11.7 19.6
Teach one or more days per month
    Yes 51.3 25.5 0.01
    No 48.7 17.4
Practice Site
    Hospital 48.0 25.0 0.02
    Solo, office based 16.3 10.4
    Single specialty group, office based 22.5 24.8
    Multispecialty group, office based 9.5 19.8
    Other, office based 3.6 10.5
% patients in managed care
    0-30 27.8 21.8 0.96
    31-50 22.7 21.5
    55-85 26.1 23.4
    87-100 23.3 19.3
Study site
    5 health maintenance organizations 8.8 21.4 0.05
    8 counties in Northern California 24.6 19.9
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Physician Characteristics Proportion of surgeons
(N=635)
% who are high-volume
surgeons P value
†
    Los Angeles County 23.2 25.3
    State of Alabama 18.4 18.8
    33 counties in North Carolina 20.5 16.9
    10 Veterans Affairs hospitals 4.6 43.5
Practice at National Cancer Institute-designated cancer center
    Yes 27.8 29.6 0.002
    No 72.2 18.5
Participate in Community Clinical Oncology Program 31.5 26.0 0.07
    Yes 68.5 19.5
    No
Attend tumor board meetings
Weekly 34.3 31.8 <0.001
Monthly 33.8 18.0
Quarterly or less frequently 31.9 15.0
*High-volume surgeons defined as performing at least 5 colorectal cancer resections per month
†
Using the Chi square test
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Table 2
Adjusted associations with high surgical volume for colorectal cancer.
Physician characteristics Adjusted odds ratio (95% confidence interval) P value*
Specialty
    General surgeon Reference --
    Surgical oncologist/colorectal surgeon 4.92 (2.94, 8.20) <0.001
Year of medical school graduation
    1952-1973 Reference --
    1974-1981 1.29 (0.67, 2.47) .44
    1982-1990 1.45 (0.75, 2.81) .27
    1991-2001 1.32 (0.67, 2.62) .42
Board certification
    No Reference --
    Yes 0.80 (0.33, 1.90) .61
Teaching
    None Reference --
    1 or more days per month 0.95 (0.59, 1.54) .84
Practice setting
    Hospital Reference --
    Solo, office based 0.53 (0.23, 1.21) .13
    Single specialty group, office based 1.51 (0.86, 2.66) .16
    Multispecialty group, office based 1.31 (0.61, 2.79) .48
    Office based, other 0.39 (0.05, 3.37) .38
Practice at National Cancer Institute-designated Cancer Center
    No Reference --
    Yes 1.58 (0.99, 2.52) .06
Practice part of Community Clinical Oncology Program
    No Reference --
    Yes 1.10 (0.69, 1.77) .68
Attend tumor board meetings
Weekly 1.62 (0.93, 2.82) 1.00 .09
Monthly (0.57, 1.75) .99
Quarterly or less frequently Reference --
Study site
    Los Angeles County Reference --
    5 Health maintenance organizations 0.62 (0.26, 1.44) .26
    8 Northern California counties 0.82 (0.45, 1.49) .51
    State of Alabama 0.62 (0.31, 1.25) .18
    22 North Carolina counties 0.45 (0.23, 0.88) .02
    10 Veterans Affairs hospitals 1.35 (0.50, 3.60) .55
*
Using logistic regression. Model included characteristics with bivariate association ≥.20, in table.
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Table 3
Unadjusted associations of colorectal cancer volume and collaborative care for decisions regarding
chemotherapy and radiation therapy
Colorectal cancer monthly
surgical volume (quartiles)
Proportion who co-manage/ decide
jointly when deciding on chemotherapy P value
* Proportion who co-manage/ decide
jointly when deciding on radiation
therapy
P value*





Using the Chi-square test.
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Table 4
Adjusted associations of surgeons’ colorectal cancer volume with collaborative care for decisions regarding
chemotherapy
Physician characteristics Adjusted odds ratio (95% confidence interval) P value*
Surgeon volume (Number of colorectal cancer resections/month)
    0-1 Reference --
    2 1.63 (1.01, 2.63) .04
    3-4 2.39 (1.46, 3.91) <0.001
    ≥5 3.48 (1.94, 6.24) <0.001
Specialty
    General surgeon Reference --
    Colorectal surgeon/Surgical Oncologist 1.87 (1.05, 3.31) .03
US or Canadian medical graduate
    No Reference --
    Yes 2.02 (1.15, 3.52) .01
Practice site
    Hospital Reference --
    Solo, office based 1.39 (0.80, 2.44) .25
    Single specialty group, office based 0.63 (0.39, 1.03) .06
    Multi- specialty group, office based 0.55 (0.29, 1.03) .06
    Office based, Other/unknown 0.95 (0.35, 2.60) .92
% patients in managed care
    0-30 Reference --
    31-50 0.53 (0.29, 0.99) .04
    55-85 0.55 (0.31, 0.97) .04
    87-100 0.50 (0.27, 0.90) .02
Practice at National Cancer Institute-designated Cancer Center
    No Reference --
    Yes 1.13 (0.74, 1.71) .58
Practice part of Community Clinical Oncology Program
    No Reference --
    Yes 1.68 (1.13, 2.51) .01
Attend tumor board meetings
    Weekly 1.66 (1.06, 2.60) .02
    Monthly 1.66 (1.08, 2.54) .03
    Quarterly or less frequently Reference --
Study site
Los Angeles County Reference --
5 Health maintenance organizations 2.29 (1.08, 4.86) .03
8 Northern California counties 1.09 (0.67, 1.79) .73
State of Alabama 1.61 (0.88, 2.94) .12
22 North Carolina counties 1.39 (0.79, 2.43) .25
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Physician characteristics Adjusted odds ratio (95% confidence interval) P value*
10 Veterans Affairs hospitals 1.17 (0.44, 3.12) .76
*
Using logistic regression. Model included characteristics with bivariate association ≤.20, in table.
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Table 5
Adjusted associations of surgeons’ colorectal cancer volume with collaborative care for decisions regarding
radiation therapy
Physician characteristics Adjusted odds ratio (95% confidence interval) P value*
Surgeon volume (Number of colorectal cancer resections/month)
    0-1 Reference --
    2 1.27 (0.79, 2.05) .32
    3-4 1.71 (1.05, 2.77) .03
    ≥5 2.27 (l.27, 4.06) .005
Specialty
    General surgeon Reference --
    Colorectal surgeon/Surgical Oncologist 1.80 (1.00, 3.22) .048
US or Canadian medical graduate
    No Reference --
    Yes 1.68 (0.97, 2.89) .06
Practice site
    Hospital Reference --
    Solo, office based 0.90 (0.52, 0.1.55) .71
    Single specialty group, office based 0.70 (0.44, 1.12) .13
    Multi- specialty group, office based 0.70 (0.38,1.29) .26
    Office based, Other/unknown 0.48 (0.18, 1.25) .13
% patients in managed care
    0-30 Reference --
    31-50 0.46 (0.25, 0.84) .01
    55-85 0.53 (0.31, 0.90) .02
    87-100 0.44 (0.25, 0.76) .003
Practice part of Community Clinical Oncology Program
    No Reference --
    Yes 1.28 (0.87, 1.88) .21
Attend tumor board meetings
    Weekly 1.82 (1.17, 2.82) .008
    Monthly 1.61 (1.07, 2.45) .02
    Quarterly or less frequently Reference --
*
Using logistic regression. Model include
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